Immatics N.V. IMTX
- anzutresgene autoleucel — Cutaneous Melanoma Phase 2
- IMA203CD8 Phase 1
- IMA402 — Cutaneous Melanoma Phase 1
- IMA402 — Ovarian Cancer Phase 1
- IMA402 — Squamous Non-Small Cell Lung Cancer Phase 1
PRAME (4 companies · 14 programs)
Companies with an active program directed at PRAME.
Immunocore Holdings plc IMCR
- brenetafusp — Cutaneous Melanoma Phase 3
- brenetafusp — Ovarian Cancer Phase 1
- brenetafusp — Non-Small Cell Lung Cancer Phase 1
- IMC-P115C Phase 1
Marker Therapeutics, Inc. MRKR
- MT-601 — Non-Hodgkin Lymphoma Phase 1
- MT-601 — Pancreatic Cancer Preclinical
- MT-401-OTS — Acute Myeloid Leukemia Phase 1
- MT-401-OTS — Myelodysplastic Syndrome Phase 1
MiNK Therapeutics, Inc. INKT
- PRAME-iNKT Preclinical